|
Mar 10
|
Top Midday Gainers
|
|
Mar 10
|
Protagonist Reports Positive Top Line Results From Phase 2b Study of Icotrokinra Showing Potential to Transform the Treatment Paradigm for Patients With Ulcerative Colitis
|
|
Mar 3
|
News Flash: 10 Analysts Think Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Earnings Are Under Threat
|
|
Mar 3
|
Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer
|
|
Mar 3
|
Takeda and Protagonist report topline outcomes from trial of rusfertide
|
|
Mar 3
|
Protagonist, Takeda Say Phase 3 Study of Rusfertide Meets Endpoints in Polycythemia Vera
|
|
Mar 3
|
Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera
|
|
Feb 22
|
Investors in Protagonist Therapeutics (NASDAQ:PTGX) have seen enviable returns of 397% over the past five years
|
|
Feb 21
|
Protagonist Therapeutics (PTGX) Tops Q4 Earnings and Revenue Estimates
|
|
Feb 21
|
Protagonist Therapeutics: Q4 Earnings Snapshot
|
|
Feb 21
|
Protagonist Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
|
|
Feb 12
|
Protagonist Therapeutics, Inc. (PTGX): A Cheap Biotech Stock to Invest In Now
|
|
Jun 9
|
Has Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Impressive Stock Performance Got Anything to Do With Its Fundamentals?
|
|
May 14
|
Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress
|
|
May 8
|
Protagonist Therapeutics Inc (PTGX) Surpasses Q1 Revenue Estimates with Strategic Collaborations
|
|
May 7
|
Protagonist Therapeutics to Participate in the Citizens JMP Life Sciences Conference and the Capital One 1st Annual Biotech/Biopharma Disruptors Event
|
|
May 7
|
Protagonist Reports First Quarter 2024 Financial Results and Provides Corporate Update
|
|
Apr 29
|
We Might See A Profit From Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Soon
|
|
Apr 16
|
Turnstone Biologics Appoints William Waddill to its Board of Directors
|
|
Apr 5
|
All You Need to Know About Protagonist Therapeutics (PTGX) Rating Upgrade to Buy
|